Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic DisordersFunding This work was funded by the intramural research program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health (NIH).
Coronavirus disease 2019 (COVID-19) has affected millions of people across the world but disproportionately and severely affects persons with metabolic disorders such as obesity, diabetes mellitus, and hypertension. In this brief review, we discuss the pathways of immune dysregulation that may lead to severe COVID-19 in persons with metabolic conditions.
24 June 2020 (online)
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Organization WH. Coronavirus disease (COVID-2019) situation reports. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Published 2020. Updated April 30, 2020. Accessed May 1, 2020
- 2 Garg S, Kim L, Whitaker M. et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. Morb Mortal Wkly Rep 2020; 69 (15) 458-464
- 3 Lighter J, Phillips M, Hochman S. et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis 2020; ciaa415
- 4 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229) 1054-1062
- 5 Shekhar S, Wurth R, Kamilaris CDC, Eisenhofer G, Barrera FJ, Hajdenberg M, et al. Endocrine Conditions and COVID-19. Horm Metab Res. 2020
- 6 Lan J, Ge J, Yu J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020; 581 (7807) 215-220
- 7 Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020; 368 (6490) 473-474
- 8 Wang N, Shi X, Jiang L. et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013; 23 (08) 986-993
- 9 Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity 2019; 50 (04) 1007-1023
- 10 Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci 2017; 13 (04) 851-863
- 11 Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev 2013; 14 (03) 232-244
- 12 Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res 2009; 58 (11) 727-736
- 13 Luo X, Zhou W, Yan X. et al. Prognostic value of C-reactive protein in patients with COVID-19. Clin Infect Dis 2020 ciaa641 DOI: 10.1093/cid/ciaa641.
- 14 Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40 (11) 1286-1292
- 15 Hundhausen C, Roth A, Whalen E. et al. Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. Sci Transl Med 2016; 8 (356) 356ra119
- 16 Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286 (03) 327-334
- 17 Luther JM, Gainer JV, Murphey LJ. et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 2006; 48 (06) 1050-1057
- 18 Chamarthi B, Williams GH, Ricchiuti V. et al. Inflammation and hypertension: the interplay of interleukin-6, dietary sodium, and the renin-angiotensin system in humans. Am J Hypertens 2011; 24 (10) 1143-1148
- 19 Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight 2019; 4 (20) e131774
- 20 Stengel A, Goebel-Stengel M, Teuffel P. et al. Obese patients have higher circulating protein levels of dipeptidyl peptidase IV. Peptides 2014; 61: 75-82
- 21 Anoop S, Misra A, Bhatt SP, Gulati S, Pandey RM, Mahajan H. High circulating plasma dipeptidyl peptidase- 4 levels in non-obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes: a case-control study. BMJ Open Diabetes Res Care 2017; 5 (01) e000393
- 22 Ryskjaer J, Deacon CF, Carr RD. et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006; 155 (03) 485-493
- 23 Zhang J, Chen Q, Zhong J, Liu C, Zheng B, Gong Q. DPP-4 inhibitors as potential candidates for antihypertensive therapy: improving vascular inflammation and assisting the action of traditional antihypertensive drugs. Front Immunol 2019; 10: 1050-1050
- 24 Zhou F, Zhang Y, Chen J, Hu X, Xu Y. Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol 2016; 791: 735-740
- 25 Roca-Ho H, Riera M, Palau V, Pascual J, Soler MJ. Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int J Mol Sci 2017; 18 (03) E563
- 26 Salem ESB, Grobe N, Elased KM. Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. Am J Physiol Renal Physiol 2014; 306 (06) F629-F639
- 27 Geerlings SE, Hoepelman AIM. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999; 26 (3-4) 259-265
- 28 Calvet HM, Yoshikawa TT. Infections in diabetes. Infect Dis Clin North Am 2001; 15 (02) 407-421
- 29 Daryabor G, Kabelitz D, Kalantar K. An update on immune dysregulation in obesity-related insulin resistance. Scand J Immunol 2019; 89 (04) e12747
- 30 Singh MV, Chapleau MW, Harwani SC, Abboud FM. The immune system and hypertension. Immunol Res 2014; 59 (1-3) 243-253
- 31 Kvakan H, Luft FC, Muller DN. Role of the immune system in hypertensive target organ damage. Trends Cardiovasc Med 2009; 19 (07) 242-246
- 32 Abboud FM, Harwani SC, Chapleau MW. Autonomic neural regulation of the immune system: implications for hypertension and cardiovascular disease. Hypertension 2012; 59 (04) 755-762
- 33 Kenney MJ, Ganta CK. Autonomic nervous system and immune system interactions. Compr Physiol 2014; 4 (03) 1177-1200
- 34 Meng J, Xiao G, Zhang J. et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 2020; 9 (01) 757-760
- 35 Zhang P, Zhu L, Cai J. et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020; DOI: 10.1161/CIRCRESAHA.120.317134.
- 36 Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med 2020; DOI: 10.1056/NEJMoa2006923.
- 37 Reynolds HR, Adhikari S, Pulgarin C. et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med 2020; DOI: 10.1056/NEJMoa2008975.